Cancer
FDA Approves Label Updates for CAR T-Cell Therapies to Reduce Patient Monitoring Requirements and Remove REMS Programs
The US FDA has approved label updates for lisocabtagene maraleucel (liso-cel; Breyanzi) in large B-cell lymphoma (LBCL) and other lymphomas, and idecabtagene vicleucel (ide-cel; Abecma) in multiple myeloma, to reduce certain patient monitoring requirements and remove the risk evaluation and mitigation strategy (REMS) programs. According to Bristol Myers Squibb, the